L26/P-753 Mild vs. intense ovarian stimulation in POSEIDON Group 2 suboptimal responders. A non-inferiority randomized controlled trial
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1080 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von N.P. Polyzos und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does mild stimulation with clomiphene citrate (CC) plus 150 IU recombinant follitropin(rFSH) result in comparable number of good-quality blastocysts(GQB) with 300 IU rFSH? Summary answer The number of GQB following mild stimulation with CC + rFSH 150 IU is non-inferior as compared with rFSH 300 IU in POSEIDON Group 2. What is known already Evidence from the past decade has established oocyte yield as a key predictor of IVF success. While strategies aimed at maximizing the number of oocytes retrieved can be easily implemented in good-prognosis patients, a low ovarian response to stimulation remains a major clinical challenge. Although prior studies have reported no differences in cumulative live birth rates between a mild and a more intense stimulation approach in predicted poor responders, there is no evidence regarding the potential role of mild stimulation in low prognosis patients with a more favorable profile such as POSEIDON Group 2. Study design, size, duration Phase IV single-center randomized non-inferiority trial conducted at a university-affiliated fertility unit (Nov 2021-Dec 2025). Overall, 110 normal-weight women aged 35–40 years with AFC 5–10 were randomized 1:1. Participants received either mild stimulation with clomiphene citrate 50 mg/day (stimulation days 1–5) plus recombinant FSH 150 IU/day from stimulation day 1, or more intense stimulation with recombinant FSH 300 IU/day throughout stimulation. Participants/materials, setting, methods In both groups, the luteinizing hormone surge was suppressed using a gonadotropin-releasing hormone (GnRH) antagonist (0.25 mg/day) from a leading follicle ≥14 mm until trigger. Final oocyte maturation was induced with recombinant human chorionic gonadotropin (hCG, 250 μg). The primary outcome was the number of good-quality blastocysts. Comparisons were made using the estimated mean difference (EMD) and corresponding 90% confidence interval (CI). Results were reported according to per-protocol analysis. Main results and the role of chance A total of 110 patients were assessed for eligibility and randomized into two groups: 55 patients were assigned to the mild stimulation(Group A), while 55 patients to the control group(Group B). In the per-protocol analysis, 100 patients were included: Group A(n = 49) and Group B(n = 51). Mean age was 37.16±1.68 and 36.88±1.64 years, in Group A and B; mean antral follicle count (AFC) was 6.93±1.68 and 6.69±2.30 respectively. Regarding stimulation outcomes, despite total dose of gonadotropins was significantly lower in mild vs. intense protocol (1462.31±435.27 vs. 2964.42±648.42; EMD -1502.11 [95% CI:−1747.41; 1256.81]), no differences were detected for number of retrieved oocytes (4.12±2.98 vs. 5.16±4.14; EMD –1.04[95% CI:−2.55;0.46]), number of MII oocytes (3.37±2.31 vs. 3.64±3.13; EMD –0.27 [95% CI:−1.42;0.88]), number of total blastocysts (1.49±1.20 vs. 1.72±1.86; EMD –0.23 [95% CI:−0.89;0.43), as well as number of cryopreserved embryos (0.88 ±1.05 vs. 1.16 ± 1.72; EMD –0.2 [95% CI: −0.87;0.32). No statistically differences were found in the mean number of GQB in the mild stimulation vs. the control group, respectively 0.60 ± 0.85 vs 0.84 ± 1.28; EMD−0.23 [90% CI: −0.62;0.15]. With the non-inferiority margin set at 1 GQB, the results demonstrate that mild stimulation is non-inferior to intense stimulation in terms of GQB obtained. Limitations, reasons for caution The sample size was powered to detect differences in the number of GQB. Findings for secondary outcomes, including pregnancy outcomes (which will be available by ESHRE 2026), should be interpreted with caution. Wider implications of the findings This is the first randomized trial comparing a mild versus more intense ovarian stimulation in POSEIDON Group2, showing that mild stimulation is non-inferior in terms of GQB. In this population, mild stimulation is a viable alternative that reduces gonadotropin exposure, potentially lowering costs and treatment burden while maintaining embryo quality. Trial registration number Yes
Zitieren
APA
Polyzos, N., Garcia-Martinez, S., Ignacio, R., & Donno, V. (2026). L26/P-753 Mild vs. intense ovarian stimulation in POSEIDON Group 2 suboptimal responders. A non-inferiority randomized controlled trial. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1080
Vancouver
Polyzos N, Garcia-Martinez S, Ignacio R, Donno V. L26/P-753 Mild vs. intense ovarian stimulation in POSEIDON Group 2 suboptimal responders. A non-inferiority randomized controlled trial. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1080
BibTeX
@article{Polyzos2026,
author = {Polyzos, N.P. and Garcia-Martinez, S. and Ignacio, R. and Donno, V.},
title = {L26/P-753 Mild vs. intense ovarian stimulation in POSEIDON Group 2 suboptimal responders. A non-inferiority randomized controlled trial},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1080}
}
EUVIMED